EVALUATION OF THE IMPACT OF METABOLIC SYNDROME ON THE COURSE AND PROGNOSIS OF PROSTATE CANCER

Prostate cancer (PCa) remains one of the most commonly diagnosed cancers in men worldwide, and its prognosis is influenced by various factors including genetic, environmental, and lifestyle-related determinants. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities including central obesity, hyperglycemia, hypertension, and dyslipidemia, which are increasingly prevalent and thought to play a role in the development and progression of various cancers. This study aims to evaluate the impact of metabolic syndrome on the course and prognosis of prostate cancer. We conducted a retrospective analysis of 200 prostate cancer patients, assessing their metabolic profile and correlating it with clinical outcomes such as tumor stage, progression-free survival, and overall survival. Our findings suggest that metabolic syndrome significantly correlates with advanced stage disease, higher Gleason scores, and shorter progression-free survival. The study underscores the importance of addressing metabolic risk factors in prostate cancer management and highlights the need for integrated treatment approaches that address both oncological and metabolic health.